Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-606.15%
operating margin TTM
-185.41%
revenue TTM
971.06 Thousand
revenue per share TTM
0.0$
valuation ratios | |
|---|---|
| pe ratio | -9.06 |
| peg ratio | 0.07 |
| price to book ratio | -8.90 |
| price to sales ratio | 56.02 |
| enterprise value multiple | -36.39 |
| price fair value | -8.90 |
profitability ratios | |
|---|---|
| gross profit margin | 93.79% |
| operating profit margin | -185.41% |
| pretax profit margin | -606.13% |
| net profit margin | -606.15% |
| return on assets | -132.15% |
| return on equity | 138.69% |
| return on capital employed | -45.17% |
liquidity ratios | |
|---|---|
| current ratio | 6.67 |
| quick ratio | 6.66 |
| cash ratio | 3.02 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 22.82 |
| operating cycle | 134.86 |
| days of payables outstanding | 466.92 |
| cash conversion cycle | -332.06 |
| receivables turnover | 3.26 |
| payables turnover | 0.78 |
| inventory turnover | 15.99 |
debt and solvency ratios | |
|---|---|
| debt ratio | 1.74 |
| debt equity ratio | -1.29 |
| long term debt to capitalization | 5.09 |
| total debt to capitalization | 4.42 |
| interest coverage | -2.33 |
| cash flow to debt ratio | -0.26 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.29 |
| cash per share | 0.37 |
| operating cash flow per share | -0.29 |
| free cash flow operating cash flow ratio | 1.02 |
| cash flow coverage ratios | -0.26 |
| short term coverage ratios | -34.38 |
| capital expenditure coverage ratio | -65.25 |
Frequently Asked Questions
When was the last time ImmunityBio, Inc. (NASDAQ:IBRX) reported earnings?
ImmunityBio, Inc. (IBRX) published its most recent earnings results on 07-05-2026.
What is ImmunityBio, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. ImmunityBio, Inc. (NASDAQ:IBRX)'s trailing twelve months ROE is 138.69%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. ImmunityBio, Inc. (IBRX) currently has a ROA of -132.15%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did IBRX's net profit margin stand at?
IBRX reported a profit margin of -606.15% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is IBRX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 6.67 in the most recent quarter. The quick ratio stood at 6.66, with a Debt/Eq ratio of -1.29.